Revance Therapeutics, Inc. (RVNC)
Feb 6, 2025 = RVNC was delisted (reason: acquired by Crown Laboratories)
3.650
0.00 (0.00%)
Inactive · Last trade price
on Feb 6, 2025
Revance Therapeutics Employees
Revance Therapeutics had 597 employees as of December 31, 2023. The number of employees increased by 63 or 11.80% compared to the previous year.
Employees
597
Change (1Y)
63
Growth (1Y)
11.80%
Revenue / Employee
$430,394
Profits / Employee
-$308,943
Market Cap
383.05M
Employees Chart
RVNC News
- 3 days ago - RVNC STOCK NEWS: Robbins LLP Reminds Revance Therapeutics, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025 - GlobeNewsWire
- 9 days ago - Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC - PRNewsWire
- 10 days ago - Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights – RVNC - GlobeNewsWire
- 15 days ago - Crown Laboratories Completes Acquisition of Revance Therapeutics - Business Wire
- 16 days ago - Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics - PRNewsWire
- 17 days ago - Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer - PRNewsWire
- 22 days ago - Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline - PRNewsWire
- 4 weeks ago - Shareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC - PRNewsWire